Press Releases

Date Title and Summary View
February 6, 2014 Eleven Biotherapeutics Prices Initial Public Offering View HTML
January 2, 2014 Eleven Biotherapeutics Adds Biotech Industry Veterans to Management Team and Board View HTML
January 2, 2014 Eleven Biotherapeutics Files Registration Statement for Proposed Initial Public Offering View HTML
December 23, 2013 Eleven Biotherapeutics Establishes Scientific Advisory Board to Guide Ophthalmic Pipeline and Technology Development View HTML
November 12, 2013 Eleven Biotherapeutics to Present Clinical Data on Lead Drug Candidate, EBI-005 View HTML
September 24, 2013 Eleven Biotherapeutics to Present at the Targeting Ocular Disorders Conference View HTML
September 20, 2013 Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients with Dry Eye Disease View HTML
September 5, 2013 Eleven Biotherapeutics to Present at the Stifel Nicolaus 2013 Healthcare Conference View HTML
June 28, 2013 Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer View HTML
June 28, 2013 Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease View HTML